In combination with capecitabine, a 5-fluorouracil pro-drug, lapatinib improved time to disease progression compared to capecitabine alone in patients with advanced HER2-positive breast cancer that had progressed on trastuzumab (Geyer et al. 2006). The gene discussed is ERBB2; the disease is breast cancer.